Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome

Inclusion Criteria: * Age; greater than 12 years old and able to cooperate for full study protocol * Subject able to understand and sign informed consent * Subject able to participate in complete ophthalmic and ocular motility evaluation * Subjects with Infantile Nystagmus Syndrome diagnosed by clinical evaluation and eye movement recordings * Best-binocular visual acuity in null position 20/50 to 20/200 inclusive using ATS or ETDRS vision testing * Subject/family able and willing to make the required study visits * No previous ophthalmic treatment for nystagmus other than for refractive error Exclusion Criteria: * Any current use of systemic or topical medications (traditional or non-traditional) * History of ocular surgery, trauma or chronic ocular disease other than amblyopia * Systemic diseases requiring medication or other treatments that are known to affect the ocular motor system (e.g., depression, seizure disorders, psychosis) * Behavioral or neurological disorders which interfere with the study * Physical or mental impairment precluding study compliance * Participation in any study involving an IND investigational drug within the past year * Individual (female) is pregnant, nursing or planning a pregnancy (The safety of Azopt for use during pregnancy has NOT been determined.) * Periodicity or aperiodicity of INS present on eye movement recordings * Allergy to sulfa or other components of Azopt solution